Orbit advises Bioventure on its launch of Club Deal 14 to invest in Repairon.

Bioventure Management’s latest club deal invests in Repairon GmbH, a pioneering biotech company on a mission to revolutionize cardiac regenerative medicine.

Repairon, a spin-off from the University Medical Center Göttingen (UMG), is developing the world’s first clinically tested “heart patch” based on Engineered Human Myocardium (EHM) – functional human heart muscle tissue grown in the lab to biologically repair damaged hearts.

Alongside Bioventure, the life science group Sartorius has increased its stake in Repairon.

Orbit advised on all legal, regulatory, and tax aspects of the structuring of Club Deal 14.

Team

Philipp Neidel (Lead Partner, Fund Structuring), Louise Hertz (Fund Associate, Fund Structuring), Laurin Kühn (Certified Tax Advisor, Tax), and Niclas Winands (Fund Associate, Fund Structuring).

‍

About Bioventure

Bioventure establishes and manages financing companies - Bioventure Club Deals - to provide investors with attractive investments in carefully selected life science companies. Visit the website for more information: Bioventure

About Orbit

Orbit offers client-centered legal advice in all areas of fund law and investments in alternative assets. Fund managers and investors rely on Orbit and its team of experienced fund advisors. Orbit covers structuring, regulatory, tax, investment advice, compliance, and fund due diligence as well as secondary transactions.

Orbit | All. About. Funds.

‍